For research use only. Not for therapeutic Use.
Bemfivastatin hemicalcium(CAT: I040642) is an orally active HMG-CoA reductase inhibitor developed as a lipid-lowering agent for the management of hypercholesterolemia. It enhances the activity of liver extracts involved in cholesterol metabolism and has demonstrated favorable safety margins with no-observed-adverse-effect levels (NOAELs) of ≥320 mg/kg/day (rat developmental toxicity), ≥12.5 mg/kg/day (rabbit maternal toxicity), and ≥25 mg/kg/day (rabbit developmental toxicity). Bemfivastatin hemicalcium is particularly valuable in statin intolerance research, offering potential in the treatment of statin-related hypercholesterolemic myalgia. It serves as a promising candidate for both preclinical evaluation and therapeutic studies targeting cardiovascular and metabolic disorders.
| CAS Number | 805241-64-9 |
| Molecular Formula | C34H37FN2O6.1/2Ca |
| Purity | ≥95% |
| Chemistry Calculators | Dilution Calculator In vivo Formulation Calculator Molarity Calculator Molecular Weight Calculator Reconstitution Calculator |
